Does LENVATINIB Cause Hepatocellular carcinoma? 16 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 16 reports of Hepatocellular carcinoma have been filed in association with LENVATINIB (Lenvima). This represents 0.1% of all adverse event reports for LENVATINIB.
16
Reports of Hepatocellular carcinoma with LENVATINIB
0.1%
of all LENVATINIB reports
4
Deaths
3
Hospitalizations
How Dangerous Is Hepatocellular carcinoma From LENVATINIB?
Of the 16 reports, 4 (25.0%) resulted in death, 3 (18.8%) required hospitalization, and 2 (12.5%) were considered life-threatening.
Is Hepatocellular carcinoma Listed in the Official Label?
Yes, Hepatocellular carcinoma is listed as a known adverse reaction in the official FDA drug label for LENVATINIB.
What Other Side Effects Does LENVATINIB Cause?
Diarrhoea (4,262)
Hypertension (4,152)
Fatigue (3,603)
Decreased appetite (3,257)
Malignant neoplasm progression (2,929)
Nausea (2,492)
Blood pressure increased (2,228)
Vomiting (1,962)
Asthenia (1,643)
Malaise (1,602)
What Other Drugs Cause Hepatocellular carcinoma?
SORAFENIB (1,665)
RIBAVIRIN (1,046)
SOFOSBUVIR (877)
LEDIPASVIR\SOFOSBUVIR (640)
BEVACIZUMAB (532)
REGORAFENIB (470)
DACLATASVIR (419)
ATEZOLIZUMAB (342)
CABOZANTINIB S-MALATE (219)
TACROLIMUS (183)
Which LENVATINIB Alternatives Have Lower Hepatocellular carcinoma Risk?
LENVATINIB vs LEPONEX
LENVATINIB vs LERCANIDIPINE
LENVATINIB vs LETAIRIS
LENVATINIB vs LETERMOVIR
LENVATINIB vs LETROZOLE